白细胞介素—2的PEG化

用自制的氨基ＰＥＧ化试剂ｒＩＬ－２进行化学修饰,研究了试剂浓度,溶液ｐＨ,反应时间间等与ＰＥＧ－ｒＩＬ－２产率及ＩＬ－２活性保持之间的关系,建立了一套获得稳定修饰度的ＰＥＧ－ｒＩＬ－２的方法,研究发现,反应时间跟修饰度关系不大;溶液ｐＨ对修饰度有一定的影响,中性ｐＨ以上反应都可进行;而试剂浓度直接决定修饰度的高低,过量越多,修饰度越高,而生物活性保留也越低;但低度修饰,对活性几乎没有影响,可保留活     

重组人白细胞介素-6的纯化

重组人白细胞介素－６（ｒｈＩＬ－６）在工程菌ｐＢＶ２２０／ｒｈＩＬ－６／ＤＨ５ａ中以包涵体形式高效表达。ｒｈＩＬ－６经过工程菌体破碎、包涵体分离及抽提、复性、色谱分离后得到高度纯化。纯化产物纯度９５％,具有良好的生物学活性     

白细胞介素－2的PEG化

用自制的氨基ＰＥＧ化试剂ｒＩＬ－２进行化学修饰,研究了试剂浓度,溶液ｐＨ,反应时间等与ＰＥｃａ－ｒＩＬ－２产率及ＩＬ－２活性保持之间的关系,建立了一套获得稳定修饰度的ＰＥＧ－ｒＩＬ－２的方法。研究发现,反应时间跟修饰度关系不大;溶液ｐＨ对修饰度有一定的影响,中性ｐＨ以上反应都可进行;而试剂浓度直接决定修饰度的高低,过量越多,修饰度越高,而生物活性保留也越低;但低度修饰,对活性几乎没有影响,可保留活性在９５％左右。     

聚乙二醇化重组人白细胞介素-6经不同途径给药的药代动力学比较研究

目的 研究聚乙二醇化重组人白细胞介素-6不同给药途径的药代动力学.方法 将大鼠分为皮下给药组、静脉给药组,每组各设3个剂量组.分别按40μg/kg、20μg/kg、3μg/kg给药.同位素示踪法用碘标记PEGrhIL-6,采用TCA沉淀法检测放射性浓度,3P87软件判断房室模型并计算各种参数,并检测125I-PEG-rhIL-6皮下注射大鼠后不同时间的血药浓度.结果 ①静脉给药大鼠体内的血药浓度-时间曲线符合二房室模型,而皮下给药大鼠体内的血药浓度-时间曲线符合一房室模型;②皮下给药的达峰时间比静脉给药慢,但其有效血药浓度维持时间较静脉给药长;③皮下给药较静脉给药各时点血药浓度低.结论 皮下给药毒性低,是一种安全可靠的给药方法;同时有效血药浓度维持时间较长,有利于治疗血小板减少症.     

重组人白细胞介素6的制备

我们采用本院基础医学研究所组建的ＩＬ-６工程菌Ｅ．ｃｏｉｌＤＨ５ａ（ｐＢＶ-ｈｌＬ－６）,在选定的培养基及ｐＨ值下,采用３０升发酵罐进一步观察了工程菌的生长和ｒＩＬ－６的表达,确定了发酵工艺条件。在此条件下连续进行了三批次的培养试验。结果表明,工程首的生长密度达到２．５１±０．０２ｇ［干重］／Ｌ［发酵液］,ｒＩＬ-６产率为１８２．４±２．０ｍｇ／ｇ［干重］。ｒＩＬ-６以包涵体形式表达于大肠杆菌细胞中,破菌后选用非离子型去垢剂或尿素等变性剂提取包涵体中的杂蛋白,可使ｒＩＬ-６的纯度达到７０．１±１．３％,收率为７１．９±１．９％。洗涤后的包涵体,经过凝胶柱纯化和复性,ｒＩＬ-６纯度达到９５％以上,柱纯化的收率为７２．３±０．９％;采用依赖ＩＬ-６,小鼠杂交瘤细胞系７ＴＤ１及ＭＴＴ比色法测定生物活性,ｒＩＬ-６比活性达２×１０８Ｕ／ｍｇ。     

重组人白细胞介素2复性条件的研究

由E.coli表达的重组白细胞介素2(rIL—2)以包涵体形式存在于工程菌胞浆中。用变性剂将包涵体溶解后得到的还原态rIL—2没有生物活性,必须对其进行复性才能最终得到有用的产品。本实验研究了以盐酸胍(GUHCl)为变性剂条件下,变性剂浓度、复性剂、pH值以及温度和时间等对rIL—2复性的影响。     

重组人白细胞介素-11工程菌的发酵条件研究

为了探讨发酵条件对大肠杆菌表达人白细胞介素-11融合蛋白的影响,利用正交实验设计,对工程菌的生长条件和人白细胞介素-11融合蛋白表达进行优化。在摇瓶中研究了培养基中的葡萄糖、蛋白胨、酵母抽提物的浓度、pH及摇床转速、装液量、接种量等。确定了工程菌生长及表达的培养基和培养条件:葡萄糖10g/L,蛋白胨20g/L,酵母抽提物10g/L,pH7.5,接种量10%,装液量10%,摇床转速220r/min及诱导时间为4~5h。然后在BiofloⅢ-5L发酵罐中以优化的发酵条件进行了3批实验,结果表明:工程菌量达到55g/L(DCW),重组人白细胞介素-11融合蛋白表达量为33%左右,为进行中试研究奠定了理论基础。     

重组人白细胞介素—2制备工艺的研究

本文对大肠杆菌表达的重组人白细胞介素-2进行了制备工艺的研究。用4mol／L脲溶解可溶性细菌蛋白后可使rIL—2包涵体纯度达70％;在变性条件下进行凝胶过滤并收集rlL－2主峰纯度可达90％;利用Cu2 氧化复性;最后用反相HPLC纯化,得到高度均一,纯度高达98％,比活达到8．0×106U／mg蛋白,且无热源,无残留DNA的rIL—2;每次反相色谱分离过程可获得400mg左右的rIL－2,得率约25％。     

白细胞介素6构象研究进展

简要介绍了人白细胞介素6(hIL-6)的一级结构和高级结构;通过对hIL-6突变体的研究,发现hIL-6分子上存在2个活性位点(位点Ⅰ和位点Ⅱ),其中位点Ⅰ识别hIL-6受体(hIL-6R)的分子量为80×10~3的配基结合亚单位,位点Ⅱ与gp130结合参与信号转导,这使得合理设计hIL-6拮抗剂成为可能。     

PEG-rhIL-6与rhIL-6在化疗模型小鼠中体内药效的比较研究

为了研究本单位研制的聚乙二醇化重组人白细胞介素-6(PEG-rhIL-6)在动物体内的药效是否优于未经修饰的重组人白细胞介素-6(rhIL-6)。将健康的雌性BALB/c小鼠分成模型对照组、rhIL-6低、中、高剂量实验组、PEG-rhIL-6低、中、高剂量实验组和空白对照组进行试验,检测小鼠用药前后血小板和体重的动态变化。结果表明PEG-rhIL-6具有减缓环磷酰胺致小鼠血小板减少的作用。高剂量的PEG-rhIL-6与高剂量的rhIL-6相比,减缓血小板减少程度的作用更强(t=2.42,P=0.017),血小板恢复也更快,显示了更好的药效作用。同时PEG-rhIL-6和rhIL-6均可抗环磷酰胺对小鼠体重增长的抑制作用。     

聚乙二醇对PEG化重组人促红细胞生成素热稳定性和生物学活性的影响

为了研究聚乙二醇对PEG化rhEPO热稳定性和生物学活性的影响,用酶学方法切除rhEPO和PEGrhEPO分子中的N连接糖基,研究酶切产物在37℃时287nm和350nm吸光度随时间的变化;用MTT比色法,网织红细胞法和HCT法比较体内和体外生物学活性的改变。结果显示聚乙二醇修饰能显著减少无N连接糖基的rhEPO分子间的聚集,降低rhEPO体外生物学活性,但增高体内生物学活性;无N连接糖基的PEG化rhEPO具有与rhEPO相当的体内生物学活性。因此聚乙二醇能提高rhEPO热稳定性;聚乙二醇可替代糖基,维持rhEPO的体内生物学活性。用PEG修饰原核细胞表达的rhEPO是开发rhEPO制品的新思路。     

重组人戊型肝炎疫苗细菌内毒素检查方法的建立

确立重组人戊型肝炎疫苗原液的细菌内毒素检查方法。供试品参照《中华人民共和国药典》(2005年版三部)热原检查法进行热原检查,结果符合规定。该供试品同时参照《中华人民共和国药典》(2005年版三部)细菌内毒素检查法要求进行试验。供试品溶液在40μg/m l浓度下,确定内毒素限值为40EU/m l。供试品在该内毒素限值下干扰试验有效,且细菌内毒素检查法符合规定。该疫苗用内毒素检查法代替热原检查法,方法可行。     

Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells

In the present study we evaluate the antitumor efficacy of a glycosylated molecule of interleukin-6 (IL-6), which was cloned and expressed in Chinese hamster ovary cells. When tested with two syngeneic murine tumors, the MC38 adenocarcinoma and the MCA106 fibrosarcoma, recombinant IL-6 (rIL-6) significantly reduced the number of day-3 established MC38 lung metastases, but had no effect on MCA106 lung metastases. A similar effect of rIL-6 was seen on day-3 MC38 liver metastases. The antitumor activity mediated by rIL-6 was achieved at doses of the cytokine ranging from 6 µg to 150 µg/day. There was no correlation between the responsiveness to rIL-6 of these two tumors and their susceptibility, in vitro, to a direct cytostatic effect of the cytokine or the increase in the expression of major histocompatibility complex (MHC) antigens after exposure to rIL-6. However, a correlation was seen between the antitumor response to rIL-6 and the initial number of tumor cells expressing MHC antigens. The possible role of MHC antigens expressed on tumor cells, the generation of MHC-restricted cytotoxic cells and the responsiveness to IL-6 are discussed.     

Expression of functional recombinant human factor IX in milk of mice

Human factor IX is synthesized in the liver and secreted in the blood, where it participates in a group of reactions involving coagulation factors and proteins that permit sanguinary coagulation. In this work two lines of transgenic mice were developed to express the FIX gene in the mammalian glands under control of milk β-casein promoter. The founding females secreted the FIX in their milk (3% total soluble protein). The stable integration of transgene was confirmed by southern blot analysis. The presence of the FIX recombinant protein in the milk of transgenic females was confirmed by western blot and the clotting activity was revealed in blood-clotting assays. The coagulation activity in human blood treated with recombinant FIX increased while the time of coagulation decreased. Our results confirm the production of a large amount of recombinant biologically active FIX in the mammary gland of transgenic mice.     

Toward improving selectivity in affinity chromatography with PEGylated affinity ligands: The performance of PEGylated protein A

Chemical modification of macromolecular affinity chromatography ligands with polyethylene glycol chains or “PEGylation” can potentially improve selectivity by sterically suppressing non‐specific binding interactions without sacrificing binding capacity. For a commercial protein A affinity media and with yeast extract (YE) and fetal bovine serum (FBS) serving as mock contaminants, we found that the ligand accounted for more than 90% of the media‐associated non‐specific binding, demonstrating an opportunity for improvement. The IgG static binding affinity of protein A mono‐PEGylated with 5.0 and 20.7 kDa poly(ethylene glycol) chains was found to be preserved using a biomolecular interaction screening platform. Similar in situ PEGylations of the commercial protein A media were conducted and the modified media was functionally characterized with IgG solutions spiked with YE and FBS. Ligand PEGylation reduced the mass of media‐associated contaminants by a factor of two to three or more. Curiously, we also found an increase of up to 15% in the average recovery of IgG on elution after PEGylation. Combined, these effects produced an order of magnitude increase in the IgG selectivity on average when spiked with YE and a two‐ to three‐fold increase when spiked with FBS relative to the commercial media. Dynamic binding capacity and mass‐transfer resistance measurements revealed a reduction in dynamic capacity attributed to a decrease in IgG effective pore diffusivity and possibly slower IgG association kinetics for the PEGylated protein A ligands. Ligand PEGylation is a viable approach to improving selectivity in affinity chromatography with macromolecular ligands. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:1364–1379, 2014     

Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles

Generation of the soluble interleukin-6 receptor (sIL-6R) is a prerequisite for pathogenic IL-6 trans-signaling, which constitutes a distinct signaling pathway of the pleiotropic cytokine interleukin-6 (IL-6). Although in vitro experiments using ectopically overexpressed IL-6R and candidate proteases revealed major roles for the metalloproteinases ADAM10 and ADAM17 in IL-6R shedding, the identity of the protease(s) cleaving IL-6R in more physiological settings, or even in vivo, remains unknown. By taking advantage of specific pharmacological inhibitors and primary cells from ADAM-deficient mice we established that endogenous IL-6R of both human and murine origin is shed by ADAM17 in an induced manner, whereas constitutive release of endogenous IL-6R is largely mediated by ADAM10. Although circulating IL-6R levels are altered in various diseases, the origin of blood-borne IL-6R is still poorly understood. It has been shown previously that ADAM17 hypomorphic mice exhibit unaltered levels of serum sIL-6R. Here, by quantification of serum sIL-6R in protease-deficient mice as well as human patients we also excluded ADAM10, ADAM8, neutrophil elastase, cathepsin G, and proteinase 3 from contributing to circulating sIL-6R. Furthermore, we ruled out alternative splicing of the IL-6R mRNA as a potential source of circulating sIL-6R in the mouse. Instead, we found full-length IL-6R on circulating microvesicles, establishing microvesicle release as a novel mechanism for sIL-6R generation.     

Performance of recombinant ESAT-6 antigen (ML0049) for detection of leprosy patients

AIMS: The study was aimed to evaluate the Mycobacterium leprae recombinant early secreted antigenic target-6 (rESAT-6) for its serological performance in leprosy patients. METHODS AND RESULTS: Employing enzyme-linked immunosorbent assay (ELISA), serum samples were tested for prevalence of immunoglobulin G antibodies against M. leprae rESAT-6. The results revealed that the sensitivity of the assay for smear-positive leprosy patients was 82.4% (14 of 17) while for smear-negative patients it was 19.4% (six of 31). Interestingly, the performance of ESAT-6-based assay was statistically comparable with anti-phenolic glycolipid-I antibody-detecting ELISA, a most widely studied serological assay in leprosy. Regarding specificity, none of the 48 controls was positive indicating that antibody response to ESAT-6 was highly specific. Moreover, a high concordance between bacterial index and anti-ESAT-6 antibody-detecting assay was noted. CONCLUSIONS: Recombinant ESAT-6 seems to be a potential serological reagent for detection of M. leprae infection. SIGNIFICANCE AND IMPACT OF THE STUDY: ESAT-6 serology may have utility for (i) early diagnosis, particularly, of highly infectious form (multibacillary, MB) of leprosy, (ii) monitoring the response in smear-positive leprosy patients during the course of the chemotherapy, (iii) classification of leprosy patients into MB and paucibacillary groups for treatment purpose. Hence, further research on these lines is warranted.     

Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study

Inhibitory effects of some drugs were investigated on human erythrocyte 6-phosphogluconate dehydrogenase obtained with a 6552-fold purification in a yield of 78% using 2′, 5′-ADP Separose 4B affinity gel. Which on SDS polyacrylamide gel electrophoresis showed a single band. Larnoxicam, metronidazole, imipenem, ornidazole, vancomycin, clindamycin, and amoxicillin exhibited inhibitory effects on the enzyme in vitro with IC₅₀ values of 0.17, 0.23, 0.43, 21.79, 46.39, 117.43 and 287.35 mM, and the Ki constants 0.40 ± 0.04, 0.57 ± 0.06, 0.77 ± 0.11, 42.40 ± 2.89, 65.60 ± 4.03, 130.22 ± 9.21, and 287.58 ± 10.56 mM, respectively. While vancomycin, clindamycin and amoxicillin showed competitive inhibition the other drugs displayed noncompetitive inhibition.